Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them
US12077526B2 · kind B2 · utility
0Cited by
20References
22Claims
0Family size
Assignees
Inventors
- Steven Howard
- Benjamin David CONS
- Jeffrey David ST. DENIS
- Rhian Sara HOLVEY
- Guillaume François PARRA
- Kim Louise Hirst
- Isabelle Anne LEMASSON
- David John Nash
- James Daniel OSBORNE
- Jonas Calleja PRIEDE
- Nicholas Paul RICHARDS
- Aaron M. Dumas
- Brian Christopher Bishop
- David Parry-Jones
- Meenakshi Sundaram Shanmugham
- Darren James DIXON
- Matthew James GAUNT
Key dates
| Filing date | Jan 25, 2023 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Jan 25, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.